AtriCure, Inc. (ATRC) stock
Close on Nov 12, 2026Market cap $2.85BP/E 186.6Yield –
AtriCure, Inc. grew revenue 13.8% to $589.80M over the twelve months to Sep 30, 2026. Free cash flow was $52.94M, up 60.4% from a year earlier. At the latest close the market valued the company at $2.85B, 186.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.85B
- P/E ratio
- 186.6
- Price to sales
- 4.83
- Price to book
- 5.34
- Dividend yield
- –
- Free cash flow yield
- 1.86%
Fundamentals
- Revenue
- $589.80M
- Net income
- $14.88M
- EPS, diluted
- $0.30
- Free cash flow
- $52.94M
- Book value per share
- $10.70
- Diluted shares
- 50M
Trading
- Next earnings
- Feb 16, 2027 (estimated, after the close)
- Previous close
- $57.53
- Open
- $57.93
- Day's range
- $55.74 – $58.23
- Volume
- 462,488
- Average volume (20 days)
- 794,900
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.26
- 52-week range
- $25.36 – $66.02
- RSI (14 days)
- 44.2
- Volatility (1 year)
- 47.6%
- Relative volume
- 0.46×
- WACC
- 11.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATRC | S&P 500 | Difference | ATRC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.3% | -2.7% | +0.4 pts | ||
| 3 months | +28.5% | -1.7% | +30.3 pts | ||
| Year to date | +41.5% | +11.9% | +29.6 pts | ||
| 1 year | +69.3% | +12.0% | +57.3 pts | ||
| 3 years | +59.6% | +78.2% | −18.6 pts | +16.9% | +21.2% |
| 5 years | -27.5% | +73.2% | −100.7 pts | -6.2% | +11.6% |
| 10 years | +180.6% | +309.6% | −129.0 pts | +10.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AtriCure filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About AtriCure
Surgical & Medical Instruments & Apparatus
AtriCure develops and markets surgical devices and therapies designed to treat atrial fibrillation, manage the left atrial appendage, and control post-operative pain. Its primary solutions include cardiac ablation platforms utilizing radiofrequency and cryogenic energy, left atrial appendage exclusion systems under the AtriClip brand, and cryoablation probes for cryo nerve block. The company offers these technologies to medical centers and specialized clinicians, including cardiac and thoracic surgeons as well as electrophysiologists, for use in open-heart, minimally invasive, and amputation procedures.
Company profile, executives and historyAtriCure stock: common questions
What is AtriCure's stock price?
ATRC closed at $55.98 on Nov 12, 2026, down 2.69% on the day. Over the past 52 weeks it traded between $25.36 and $66.02.
What is AtriCure's market cap?
AtriCure was worth $2.85B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ATRC's P/E ratio?
ATRC trades at 186.6 times earnings, based on diluted earnings per share of $0.30 over the twelve months to Sep 30, 2026.
How much revenue does AtriCure make?
AtriCure reported revenue of $589.80M for the twelve months to Sep 30, 2026, up 13.8% from a year earlier.
Does AtriCure pay a dividend?
No. AtriCure has not paid a cash dividend over the last twelve months.
When does AtriCure report earnings next?
AtriCure is expected to report Q4 FY2026 results on Feb 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ATRC stock performed over the past year?
Including dividends, ATRC returned +69.3% over the past year, against +12.0% for the S&P 500.
How many ATRC shares are sold short?
5M shares were sold short at the latest FINRA report, 10.02% of the float, or 7.6 days of average trading volume.
Who are AtriCure's competitors?
Companies most similar to AtriCure by business, industry and size include AORT, ANGO, BVS, LMAT, ATEC.
See a number that looks wrong?